Phase 2 N=41 Catheter Related - Gram Positive Bloodstream Infections
Bloodstream Infection
Primary: Clinical Response Within 48 Hours — 28 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=201 Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
Infections, Gram-positive Bacterial
Primary: Clinical Response Which is Measured at Test of Cure (TOC) in the Clinically Evaluable (CE) Population — 74; 72; 3; 5 participants — p=0.5318
Phase 2 N=122 Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections
Infections, Bacterial
Primary: Number of Participants With Composite of the Cure Rate as Measured by Clinical Response and Outcome at the Early Efficacy Visit Combined With Withdrawal Rate — 48; 28…
N/A N=25 Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections
Fasciitis, Necrotizing · Severe Necrotizing Skin and Soft Tissue Infections · Fournier's Gangrene
Primary: Clinical Response to High Dose Daptomycin Therapy at End of Treatment (EOT) — 16; 0; 2; 0 Participants
Phase 2 N=169 Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
Infections, Gram-Positive Bacterial · Abscess · Burns
Primary: Clinical Response Which is Measured at Test of Cure (TOC) in the Clinically Evaluable (CE) Population — 66; 66; 6; 3 participants — p=0.5289
N/A N=500 Effect of Direct-from-blood Bacterial Testing on Antibiotic Administration and Clinical Outcomes
Bloodstream Infection · Sepsis Bacterial · MRSA Bacteremia
Primary: Time to Last Dose of Intravenous Vancomycin — 19.0; 12.5 time in hours
Phase 3 N=199 Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA
Methicillin-Resistant Staphylococcus Aureus · Bacterial Infections · Staphylococcal Skin Infections
Primary: Shift From Baseline in Distortion Product Otoacoustic Emission at TOC Visit — 2; 1; 0; 0 Participants
Phase 3 N=68 Group B Streptococcus Response After Probiotic Exposure
Group B Strep Infection
Primary: GBS Culture Result (Positive Versus Negative) — 3; 6; 18; 19 Participants
Phase 2 N=330 Study of Debio 1450 for Bacterial Skin Infections
Bacterial Infections
Primary: Early Clinical Response Rate (ECRR): Percentage of Responders to Treatment at 48 to 72 Hours From Randomization as Assessed by the Investigator — 94.6; 90.1; 91.1…
Phase 2 N=120 TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection
Skin and Subcutaneous Tissue Bacterial Infections · Gram-Positive Bacterial Infections
Primary: Early Clinical Response at the Early Assessment (EA) Visit in the Intent-to-Treat (ITT) Population — 61; 27; 4; 3 Participants
Phase 3 N=265 China Registration Study in Patients With Skin Infections
Skin Diseases · Infectious
Primary: Change of Erythrocyte Volume Fraction(Percentage of Erythrocyte Volume in Total Volume of Blood) — 0.00; 0.01 percentage
Phase 4 N=146 Preventing Staphylococcal (Staph) Infection
Staphylococcal Infections
Primary: Re-infection With S. Aureus — 10; 11; 0; 0 participants with S. aureus re-infection — p=0.356
Phase 4 N=1,077 Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)
Skin/Soft Tissue Infections · Methicillin Resistant Staphylococcus Aureus (MRSA)
Primary: Clinical Outcome in Participants With Baseline Methicillin-Resistant Staphylococcus Aureus (MRSA) at End of Study (EOS) for Per-Protocol (PP) Population — 84.1; 79.9…
Phase 2 N=1,379 GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults
Sepsis
Primary: Percentage of Participants With 28-Day All Cause Mortality — 26.9; 25.8; 31.3 Percentage of participants — p=0.329
Phase 3 N=739 Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Abscess · Wound Infection · Surgical Site Infection
Primary: Early Clinical Efficacy — 285; 288; 86; 80 participants
Phase 3 N=573 Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Abscess · Wound Infection · Surgical Site Infection
Primary: Early Clinical Efficacy — 240; 233; 48; 52 participants
Phase 2 N=52 Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects.
Staphylococcus Aureus Bacteremia
Primary: Number of Participants Who Experienced Dose-limiting Toxicities — 0; 0; 0; 0 participants
N/A N=271 Impact of a Procalcitonin Testing and Treatment Algorithm on Antibiotic Use and Outcomes in the Pediatric Intensive Care Unit
Sepsis · Procalcitonin · Antimicrobial Stewardship
Primary: Days of Antibiotic Therapy in the First 14 Days Following Randomization — 7.6; 6.6 days
Phase 2 N=200 DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia
Staphylococcal Bacteraemia
Primary: Desirability of Outcome Ranking (DOOR) — 49; 49; 34; 37 Participants
Phase 2 N=509 Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
Bacteremia
Primary: Cure Rate — 207; 209 Participants
Phase 2 N=56 Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia
Bacteremia · Staphylococcus Aureus · Staphylococcus Aureus Bacteremia
Primary: Number of Participants With Treatment-Emergent Adverse Events (Safety and Tolerability) Following Multiple Doses of Intravenous AP-Sa02. — 17; 10; 6; 2 number of…
N/A N=120 Bacterial Resistance in Patients Receiving Post-Intravitreal Injection Antibiotics
Bacterial Resistance
Primary: Number of Participants With Resistance of Ocular Flora to Commonly Used Post-injection Prophylactic Antibiotics — 10; 6 Participants
N/A N=33 Enhanced, Personalized and Integrated Care for Infection Management at the Point-Of-Care
Antibiotic Resistant Infection · Infection
Primary: Percentage of Appropriate Antimicrobial Prescriptions Recommended — 90 percentage of prescriptions appropriate
Phase 2 N=39 Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients
Infection · Bacteremia
Primary: Patient Clinical Response to Telavancin — 32 Participants
N/A N=120 Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Community Acquired Pneumonia
Pneumonia
Primary: Use of Antibiotics in Each Group — 28; 52 participants
N/A N=31 Trial of Antibiotic Treatment for Skin Abscess in Patients at Risk for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection
Abscess
Primary: Clinical Improvement at 7 Days After Incision and Drainage — 10; 14 participants
Phase 4 N=249 Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA
Staphylococcal Skin Infections
Primary: Infection-Related Hospital Length of Stay — 91.46; 93.23 Hours
N/A N=80 Skin Prep to Reduce Postoperative Shoulder Infection
Shoulder Infection
Primary: Skin Swab and Culture With Colony Forming Units (CFUs) — 39; 51; 35; 22 negative skin cultures — p=0.68
Phase 4 N=100 Evaluation of Daptomycin for the Emergency Department Treatment of Complicated Skin and Skin Structure Infections
Cellulitis · Skin Infections
Primary: Satisfaction of Discharge Criteria — 15; 14 participants
Phase 3 N=939 Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus
Staphylococcal Skin Infection
Primary: Clinical Response — 358; 364; 59; 57 patients